Will BMA (British Medical Association) fireworks throw light on medtech-hitting reforms?
This article was originally published in Clinica
The annual representative meeting of the British Medical Association (BMA), which got underway today in Belfast, will air deep misgivings over healthcare reforms that impinge on the medical technology industry's position at the sharp end of cost-cutting measures.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.